Spero Therapeutics (SPRO) 10-K2022 FY Annual report

Filed: 30 Mar 23, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: atypical, bankruptcy, Basilea, Bayer, Beirut, bioprinting, biosimilar, CMO, complaint, complement, Creek, delist, delisted, delisting, Eastern, ESPR, exceeded, extinguishment, fellow, Footnote, Germond, GGL, Glaxo, GS, Hamed, inefficiency, IRA, judgement, Kamal, Kashif, language, LCM, lieu, lifespan, living, LRMR, Lysovant, Mahadeiva, Memon, men, microphysiological, misdiagnosed, misleading, motion, Nabil, overhead, PBM, Pharmaceutica, Philabundance, PHSA, plaintiff, purported, quotation, refocusing, reprogrammed, Richard, Roivant, Saad, silico, slope, SPA, spearheading, sputum, standstill, stewardship, therefrom, tranched, Triana, underway, unspecified, vaccination, vaccine, vigorously, VRTX, weekly, withdrew, Wood, wrongdoing

Removed: Adjemian, aerobic, anaerobic, beta, carnitine, cefditoren, cephalosporin, choose, collaborating, commenced, comparator, comparison, complying, contractually, cooperative, COPD, core, count, criterion, declined, deduction, defining, denominated, deposit, desire, diagnosed, differentiated, discharge, Diversify, efficiently, emerge, emergency, enrolling, Enterobacteriaceae, entrench, estimable, exploratory, fecal, Fine, flora, foregoing, gastrointestinal, geographical, golden, gram, highlighted, HIV, home, hypothetically, integrate, intestinal, irrevocably, Japanese, Jumpstart, Klebsiella, lactam, Landlord, leasehold, loose, LPAD, masquerading, mention, metabolize, metabolized, ml, nearest, nonbinding, nonconvertible, nondisruptive, Obama, observational, Orapenem, ordinarily, paper, parachute, played, preceded, productivity, prolongation, prominently, provisional, Pty, QT, quantitative, realization, receivable, redemption, refund, renewal, reversed, revised, rounded, scheduled, Serratia, sp, strain, Strollo, subscribe, suffering, suggestive, surfaced, sustaining, takeover, temporarily, tenant, TID, toxin, Trump, underwriting, undiscovered, uniformly, unnecessary, urgency, urine, view, visit, vote, Wuhan

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated SPRO transcripts

SPRO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Spero Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Annual Report for the year ended December 31, 2022 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.


	Dated: March 30, 2023	/s/ Ankit Mahadevia, M.D.
		Ankit Mahadevia, M.D.
		President and Chief Executive Officer
		(Principal Executive Officer)


	Dated: March 30, 2023	/s/ Satyavrat Shukla
		Satyavrat Shukla
		Chief Financial Officer and Treasurer
		(Principal Financial Officer and Principal Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.